Neurocrine Biosciences (NBIX) Share-based Compensation Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Share-based Compensation Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.47% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 47.06% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 8.79% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 281.05% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 92.83% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 5.49% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 61.54% |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 438.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.49% |
| Sep 30, 2025 | -187.93% |
| Jun 30, 2025 | 248.73% |
| Mar 31, 2025 | 18.65% |
| Dec 31, 2024 | 48.88% |
| Sep 30, 2024 | 151.26% |
| Jun 30, 2024 | -151.82% |
| Mar 31, 2024 | 11.53% |
| Dec 31, 2023 | 134.41% |
| Sep 30, 2023 | -63.12% |
| Jun 30, 2023 | 285.14% |
| Mar 31, 2023 | 7.84% |
| Dec 31, 2022 | -464.04% |
| Sep 30, 2022 | 249.33% |
| Jun 30, 2022 | -181.32% |
| Mar 31, 2022 | 131.25% |
| Dec 31, 2021 | 69.52% |
| Sep 30, 2021 | -53.04% |
| Jun 30, 2021 | 299.56% |
| Mar 31, 2021 | -29.82% |